Mitsubishi Chemical Holdings
Brief Company Profile
Established in 2005, Mitsubishi Chemical Holdings (MCHC) group manages several entities in performance products, industrial materials and healthcare businesses. Under its umbrella, the group has Mitsubishi Chemical Holdings Corporation, Mitsubishi Chemical Corporation, Mitsubishi Tanabe Pharma Corporation, Life Science Institute, Inc. and Taiyo Nippon Sanso Corporation etc. The group is headquartered in Tokyo, Japan and employs over 72,000 people across the world.
MCHC Group Structure
MCHC sites across the world (subsidiaries and affiliates)
MCHC has three main business segments with focus of different markets such as Automobiles, Aircraft, IT, Electronics, Displays, Medical, Food, Bio Products, Healthcare, Environment, Energy, Packaging, Labels and Films etc.
MCHC provides high performance products and solutions including polyester films, poly-vinyl alcohol film for LCD, high performance films, water treatment system & services, engineering plastic products, carbon fiber and composite materials, alumina fibers, performance polymers, engineering polymers, performance chemicals, food ingredients, Li-ion battery materials, energy transduction materials etc.
Methyl Methacrylates (MMA) and its derivatives, Polymethyl Methacrylates (PMMA), polyolefin, coke, needle coke/tar, industrial gases are few of the products provided by MCHC under this segment.
MCHC develops various pharmaceuticals, vaccines, over-the-counter medicines/products, capsules and pharmaceutical equipment, active pharmaceutical ingredients and intermediates.
Revenue break-up by segments
For the year ended 31st March 2020, MCHC's total revenue was JPY 3.6 trillion.
In terms of USD, MCHC's revenues in 2019 clocked $ 32.8 billion.
Average exchange rate USD to JPY in 2019: 108.95
Total R&D expenditure during the last fiscal was JPY 133.4 million less by 6.6% as compared to that of JPY 142.8 million during the previous year.
Revenues from overseas markets comprised around 42.9% in 2019. This share has been consistent over the last five years.
Source: MCHC Annual Report 2019.
Financial year for MCHC ends on March 31st. The next results, for the first quarter, are expected in August 2020.
The management at MCHC expects -
Lower demand for performance products
Lower market prices raw material prices to hit chemicals segment
Lower demand for both industrial gases and healthcare products
Overall, the outlook for the fiscal 2020 is not encouraging and the revenues are projected to decrease by 7-8% during the period.
Recent Investment Activities
September 2019 - Diamond Edge Ventures (DEV), an innovation investment arm of MCHC invested Denmark based AddiFab ApS, a 3D printing technology company.
March 2019 - Through its wholly owned subsidiary Matheson Tri-Gas, Inc. Taiyo Nippon Sanso Corporation completed its acquisition of HyCO (Hydrogen and Carbon Monoxide) business and its related assets in the US from Linde plc. The transaction involved acquisition of 8 HyCO plants, pipelines and supervision systems for USD 413 million.
For a detailed, customized company profile, research reports, please submit your requirements below.